Eli Lilly’s COVID-19 therapies to enter clinical trials
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational antibody will enter clinical trials in US COVID-19 patients later this month.
List view / Grid view
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational antibody will enter clinical trials in US COVID-19 patients later this month.
A new report has revealed that Germany is set to lead the aseptic sampling market in Europe, contributing $35.7 million to the market until 2025.
The developers of the novel formulation, containing the cannabinoids CBDV and CBGA, now intend to test the clinical safety and efficacy of its anti-cancer activity.
Sanofi will provide its S protein antigen and GSK will contribute its adjuvant technology in a partnership to develop a COVID-19 vaccine.
Despite some positive results from clinical trials for COVID-19 treatments, separate tests of the same therapies have not met primary endpoints.
The FDA has handed a warning letter to an Indian manufacturing facility for inadequate sterility testing and environmental monitoring.
A blood purification system to reduce cytokine storms in COVID-19 patients has been given emergency use authorisation by the FDA.
Researchers have developed a novel microrobot made from bacteria and red blood cells which they say could be an effective form of drug delivery.
The active air sampler market, led by Asia-Pacific, Europe and US, is expected to grow from its current value of $92 million at a CAGR of 5.1 percent.
The FDA has approved a clinical trial to study COVID-19 patients administered with umbilical cord-derived mesenchymal stem cells, which should prevent lung inflammation.
The COVID-19 EMA pandemic Task Force (COVID-ETF) will aid in the development, authorisation and safety monitoring of COVID-19 vaccines and therapeutics.
An Irish partnership between academia and industry aims to develop a robotic method for automated environmental monitoring in bioprocessing.
A new method has been developed by researchers which they say could allow E. coli and other pharmaceuticals to be produced in space, using shearing force and a viscometer.
The European Commission has granted Esperion approval for Nilemdo, the company has sold commercialisation rights to Daiichi Sankyo.
The US Food and Drug Administration (FDA) issued the letter after finding the products contain chlorine dioxide, a powerful bleaching agent with potentially fatal side effects.